Literature DB >> 29437609

Crump M, Neelapu SS, Farooq U, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-1808.

.   

Abstract

Year:  2018        PMID： 29437609      PMCID： PMC5794504          DOI： 10.1182/blood-2017-11-817775

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

1.  Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial.

Authors:  Jeremy S Abramson; Tanya Siddiqi; Jacob Garcia; Christine Dehner; Yeonhee Kim; Andy Nguyen; Sophie Snyder; November McGarvey; Matthew Gitlin; Corey Pelletier; Monika P Jun
Journal:  Blood Adv       Date:  2021-03-23

2.  CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison.

Authors:  Peter Dreger; Sascha Dietrich; Maria-Luisa Schubert; Lorenz Selberg; Andrea Bondong; Mandy Wegner; Peter Stadtherr; Christoph Kimmich; Florentina Kosely; Anita Schmitt; Petra Pavel; Nora Liebers; Thomas Luft; Ute Hegenbart; Aleksandar Radujkovic; Anthony Dick Ho; Carsten Müller-Tidow; Michael Schmitt
Journal:  Blood Adv       Date:  2020-12-22

3.  Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Authors:  Sattva S Neelapu; Caron A Jacobson; Olalekan O Oluwole; Javier Munoz; Abhinav Deol; David B Miklos; Nancy L Bartlett; Ira Braunschweig; Yizhou Jiang; Jenny J Kim; Lianqing Zheng; John M Rossi; Frederick L Locke
Journal:  Blood       Date:  2020-06-04       Impact factor: 22.113

4.  Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial.

Authors:  Stephen J Schuster; Richard T Maziarz; Elisha S Rusch; Junlong Li; James E Signorovitch; Vadim V Romanov; Frederick L Locke; David G Maloney
Journal:  Blood Adv       Date:  2020-04-14

Review 5.  C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.

Authors:  Caron A Jacobson; Marcela V Maus
Journal:  Blood Adv       Date:  2020-11-24

6.  Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma.

Authors:  Laetitia Vercellino; Roberta Di Blasi; Salim Kanoun; Benoit Tessoulin; Cedric Rossi; Maud D'Aveni-Piney; Lucie Obéric; Caroline Bodet-Milin; Pierre Bories; Pierre Olivier; Ingrid Lafon; Alina Berriolo-Riedinger; Eugenio Galli; Sophie Bernard; Marie-Thérèse Rubio; Celine Bossard; Veronique Meignin; Pascal Merlet; Pierre Feugier; Steven Le Gouill; Loic Ysebaert; Olivier Casasnovas; Michel Meignan; Sylvie Chevret; Catherine Thieblemont
Journal:  Blood Adv       Date:  2020-11-24

Review 7.  Immunotherapy with cells.

Authors:  Elise A Chong; David L Porter
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

8.  Chidamide and sintilimab combination in diffuse large B-cell lymphoma progressing after chimeric antigen receptor T therapy.

Authors:  Yuan-Yuan Hao; Pan-Pan Chen; Xiang-Gui Yuan; Ai-Qi Zhao; Yun Liang; Hui Liu; Wen-Bin Qian
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

9.  Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.

Authors:  Cecilia Carpio; Reda Bouabdallah; Loïc Ysebaert; Juan-Manuel Sancho; Gilles Salles; Raul Cordoba; Antonio Pinto; Mecide Gharibo; Drew Rasco; Carlos Panizo; Jose A Lopez-Martin; Armando Santoro; Antonio Salar; Silvia Damian; Alejandro Martin; Gregor Verhoef; Eric Van den Neste; Maria Wang; Suzana Couto; Soraya Carrancio; Andrew Weng; Xuehai Wang; Frank Schmitz; Xin Wei; Kristen Hege; Matthew W B Trotter; Alberto Risueño; Tonia J Buchholz; Patrick R Hagner; Anita K Gandhi; Michael Pourdehnad; Vincent Ribrag
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

10.  Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.

Authors:  Mehdi Hamadani; John Radford; Carmelo Carlo-Stella; Paolo F Caimi; Erin Reid; Owen A O'Connor; Jay M Feingold; Kirit M Ardeshna; William Townsend; Melhem Solh; Leonard T Heffner; David Ungar; Luqiang Wang; Joseph Boni; Karin Havenith; Yajuan Qin; Brad S Kahl
Journal:  Blood       Date:  2021-05-13       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.